Companion Animal Osteoarthritis Market Size, Share, Trend, Industry Analysis Report By Animal (Canine, Equine, Feline), By Product, By Route of Administration, By End Use, By Region – Market Forecast, 2025–2034

The companion animal osteoarthritis market size is expected to reach USD 18.45 billion by 2034, according to a new study by Polaris Market Research. The report “Companion Animal Osteoarthritis Market Size, Share, Trend, Industry Analysis Report By Animal (Canine, Equine, Feline), By Product, By Route of Administration, By End Use, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The companion animal osteoarthritis market addresses the growing demand for medical solutions targeting degenerative joint conditions in pets, particularly dogs and cats. Osteoarthritis, a chronic and progressive disease, is a leading cause of mobility loss and pain in aging animals. The market is gaining momentum due to increasing awareness among pet owners, a rise in veterinary consultations, and improved diagnostic capabilities. Growth is supported by advancements in pharmaceutical formulations, including long-acting injectable and anti-inflammatory medications that enhance treatment compliance and quality of life for pets.

Veterinarians are integrating regenerative therapies such as platelet-rich plasma (PRP) and stem cell applications to manage inflammation and promote joint repair. Increasing emphasis on early intervention and multimodal pain management is influencing the development of combination therapies involving drugs, dietary supplements, and physical rehabilitation. Market participants are responding to demand for noninvasive options and breed-specific solutions that address varying risk profiles. Digital tools for monitoring activity levels and mobility are emerging as supportive technologies, enabling better treatment tracking and caregiver engagement. Opportunities continue to grow in preventive care, particularly in the development of joint health supplements and wellness plans for senior pets. The rising trend of pet humanization is pushing manufacturers to prioritize safety, palatability, and evidence-based efficacy. Evolving veterinary guidelines and collaboration between veterinary practices and pharmaceutical companies are driving product innovation and clinical adoption.

Companion Animal Osteoarthritis Market Report Highlights

By product, the biologics segment accounted for ~54% of the revenue share in 2024 due to their ability to target the underlying causes of osteoarthritis rather than just alleviating symptoms.

Based on animal, the canine segment held the largest revenue share in 2024 due to the high incidence of osteoarthritis, particularly in aging and large-breed animals.

In 2024, North America accounted for the largest revenue share due to high pet healthcare spending, advanced veterinary infrastructure, and strong awareness of chronic joint conditions in companion animals.

The Asia Pacific companion animal osteoarthritis market is expected to grow significantly from 2025 to 2034 due to rising pet adoption, expanding middle-class income, and increasing awareness of animal health.

A few global key players include Boehringer Ingelheim International GmbH, Ceva, Dechra Pharmaceuticals PLC., Elanco, Eltech K-Laser s.r.l., NexGen Pharmaceuticals, Norbrook, Vetoquinol, Virbac, and Zoetis.

Polaris Market Research has segmented the companion animal osteoarthritis market report on the basis of product, animal, route of administration, end use, and region:

By Product Outlook (Revenue, USD Billion, 2020–2034)

Biologics

Stem Cells

Platelet-Rich Plasma (PRP)

Monoclonal Antibodies (mAb)

Other Biologics

Viscosupplements

Pharmaceuticals

Steroids

NSAIDS

Others

Nutritional Supplements

By Animal Outlook (Revenue, USD Billion, 2020–2034)

Canine

Equine

Feline

By Route of Administration Outlook (Revenue, USD Billion, 2020–2034)

Oral

Injectable

Others

By End Use Outlook (Revenue, USD Billion, 2020–2034)

Veterinary Hospitals/Clinics

E-commerce

Others

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa Show more